Severe asthma greatly affects patients' quality of life. Major advances have occurred in the
management of severe eosinophilic asthma the past few years due to the new targeted …

Add-on biological therapy has proven to be effective in many patients with severe
eosinophilic asthma. In this observational multicenter retrospective study, we report the …

Asthma is a chronic and heterogeneous disease, which is defined as severe disease
whenever it requires treatment with a high dose of inhaled corticosteroids plus a second …

A marked heterogeneity is exhibited by asthma both clinically and at the molecular level with
different phenotypes driven by diverse mechanistic pathways that require specifically …

The current developments of the new biological drugs targeting interleukin 5 (IL‐5) and IL‐5
receptor allowed to expand the treatment options for severe hypereosinophilic asthma …

Severe asthma is a heterogeneous disease with different phenotypes based on clinical,
functional or inflammatory parameters. In particular, the eosinophilic phenotype is …

Interleukin 5 (IL-5) is a major cytokine responsible for eosinophil proliferation, migration and
degranulation. Eosinophils play a considerable role in the manifestation of type 2 asthma …

Within the context of the heterogeneous phenotypic stratification of asthmatic population,
many patients are characterized by moderate-to-severe eosinophilic asthma, not adequately …

Severe refractory asthma (SRA) still has a high economic and social impact, including a
reduction in quality of life (QoL), productivity, a greater risk of exacerbations and emergency …

Abstract Background Interleukin-5 (IL-5) antibodies represent a promising therapeutic option
for patients with severe eosinophilic asthma. To date, no official treatment response criteria …